FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes
The basal insulin gives adults with type 2 diabetes a weekly injection option in place of daily long-acting shots.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 25 11:25 ETSource: STAT
The wire
- 01The FDA approved Eli Lilly's Onswik, a once-weekly basal insulin for adults with type 2 diabetes, STAT reported.
- 02Weekly basal dosing changes injection burden and refill cadence for prescribers, pharmacists and patients managing insulin regimens.
- 03Pricing, payer coverage and launch timing were not detailed in the report; real-world titration practice with weekly basal insulin remains to be established.
From the source
Read at statnews.comSTAT+: Lilly wins approval for once-weekly insulin shot
The FDA approved Eli Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes, offering patients an alternative to daily long-acting insulin injections.
